MiMedx (MDXG)
Processor of donated placental tissue into allografts for wound care and surgical use.
Something off on this page? Send us feedback.
Turns donated placental and umbilical tissue into allografts for wound care and surgical use, marketed under brands such as EpiFix and AmnioFix and processed through proprietary PURION technology. Sales are concentrated in the United States and priced largely against Medicare fee schedules, with Japan the lead international market.
Processes donated placental membrane, umbilical cord, and placental-disc tissue into allografts for wound and surgical care, sold under brands including EpiFix, AmnioFix, EpiCord, and the newer Heliogen xenograft line, all built on proprietary PURION tissue processing.
A 2018 accounting scandal triggered a Nasdaq delisting and the eventual criminal conviction of the founding CEO; a rebuilt leadership team restored internal controls and returned to Nasdaq trading in 2020. Newer surgical-line launches now sit alongside the original wound-care franchise.
Domestic sales make up substantially all of the top line, with Japan established as the lead international market after EpiFix became the first amniotic wound-care tissue product approved there. Products are regulated by the FDA as human tissue allografts, exempt from premarket clinical trials but priced largely off Medicare fee schedules.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 27, 2026 | Craig-Hallum | Reiterate | Rating: —Target: — | Target: $8 |
| Aug 17, 2026 | Seaport Global | Downgrade | Rating: — | |
| Aug 17, 2026 | Raymond James | Target | Target: — | Target: $8 |
| Jul 30, 2026 | Lake Street | Reiterate | Rating: —Target: $12 | Target: $7 |
| Feb 23, 2026 | UBS | Target | Target: — | Target: $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $135.8M · Total debt $1.5M · Total assets $281.0M · Shareholders' equity $216.0M
- Revenue
- $64.4M
- Operating income
- −$18.5M
- Net income
- −$14.8M
No dividends on record.
| Institutions | 77.62% | 113.14M shares | |
|---|---|---|---|
| 230 holders · as of Jun 30, 2026 | |||
| Insiders | 2.89% | 4.21M shares | |
| 12 holders · as of Jul 7, 2026 | |||
| Other | 19.49% | 28.41M shares | |
| remainder | |||
145.76M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Essex Woodlands Management, Inc.Institution | 19.34% | 28.20M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.34% | 12.15M | as of Jun 30, 2026 |
Management LLCInstitution | 5.82% | 8.48M | filed Feb 13, 2019 |
Trigran Investments, Inc.Institution | 4.92% | 7.17M | as of Jun 30, 2026 |
Group One Trading, LPInstitution | 4.38% | 6.38M | filed Jan 31, 2019 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 6, 2025 | Kimberly Maersk-Moller | officer: Chief Commercial Officer | −58,300 | $7.42 |
- Organogenesis
Head-to-head in placental allografts and bioengineered skin substitutes
- Integra LifeSciences
Amniotic allografts, bovine xenografts, and surgical matrices overlap broadly
- Smith & Nephew (ADR)
GRAFIX/STRAVIX placental allografts plus a broad wound-care portfolio
- Vericel
Cultured epidermal autografts and eschar removal overlap in severe burn care
- Solventum
Negative-pressure therapy and dressings vie for the same wound-care budgets
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MiMedx | $4.88 | +1.45% | $701.1M | 120.2 | 49.1 | 2.0 | −34.7% |
| Organogenesis | $1.48 | +6.06% | $180.1M | — | — | 0.4 | −56.7% |
| Integra LifeSciences | $15.95 | +2.28% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Smith & Nephew (ADR) | $27.47 | −0.79% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Vericel | $40.17 | +1.57% | $2.03B | 84.5 | 60.0 | 6.6 | +22.5% |
| Solventum | $88.97 | +0.15% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Median | 19.0 | 13.1 | 1.8 | +2.2% |